Lowering insulin prices isn’t the (only) answer to helping patients with diabetes
It is time to shift the conversation, incentives, and policy solutions to help people improve their health and get off of medications—not just make them cheaper.
Despite $35 insulin cap being popular, and bipartisan, Congress may not pass it
The idea of helping millions of Americans with diabetes afford a crucial medicine has immense public support and even bipartisan adherents. But then, there is politics — between Democrats and Republicans, of course, but also among Democrats.
presented by
How to Improve Employee Benefits While Reducing Insurance Costs
Balancing healthcare benefits and insurance costs requires research. From becoming a Difference Card member to offering wellness resources, there are many ways to improve healthcare at low cost.
Can changing rebate rules stop the ‘carousel’ of insulin pricing hikes?
At an event during the annual American Diabetes Association Scientific Sessions in San Francisco, representatives from PBM, health plan, drug manufacturing and patient advocacy groups came together to discuss the causes of increasing insulin prices and potential solutions to the problem.